Luqman Hakim Andira
Research Subjects
Luqman Hakim Andira has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alqi Yutha
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga—Dr Soetomo General Hospital , Mayjen Prof. Dr Moestopo Street No. 47, Surabaya 60132, Indonesia
1 shared publication - Bambang Pujo Semedi
Department of Anesthesiology and Reanimation, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
1 shared publication - Dita Aulia Rachmi
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga—Dr Soetomo General Hospital , Mayjen Prof. Dr Moestopo Street No. 47, Surabaya 60132, Indonesia
1 shared publication - Eka Prasetya Budi Mulia
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Hospital, Surabaya, Indonesia
1 shared publication - Irma Maghfirah
Universitas Airlangga
1 shared publication - Mochamad Yusuf Alsagaff
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia Department of Cardiology and Vascular Medicine, Universitas Airlangga Hospital, Surabaya, Indonesia
1 shared publication
Latest Publications
- Open Access
- 3 August 2022
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 8 (8) , 909-918
Low molecular weight heparin is associated with better outcomes than unfractionated heparin for thromboprophylaxis in hospitalized COVID-19 patients: a meta-analysis
This study aimed to compare the outcomes of administration of LMWH and UFH in hospitalized COVID-19 patients. We systematically searched several databases and included observational studies or clinical trials that compared the outcomes of administration of LMWH and UFH in hospitalized COVID-19 patients. A total of nine studies comprising 9637 patients were included. Metanalysis showed that LMWH administration was associated with a lower in-hospital mortality, and 28/30-day mortality compared with UFH administration ([RR 0.44; 95%CI 0.32–0.61; I2:87.9%] and [RR 0.45; 95%CI 0.24–0.86; I2:78.4%], respectively). Patient with LMWH had shorter duration of hospital and ICU length of stay compared with UFH ([WMD −2.20; 95%CI −3.01 to −1.40; I2:0%] and [WMD −1.41; 95%CI −2.20 to −0.63; I2:0%], respectively). The risk of ICU admission or mechanical ventilation was lower in patients who received LMWH than those who received UFH (RR 0.67; 95%CI 0.55–0.81; I2:67.3%). However, there was no difference in the incidence of bleeding with LMWH compared with UFH (RR 0.27; 95%CI 0.07–1.01; I2:64.6%). Our meta-analysis showed that administration of LMWH was associated with better outcomes compared with UFH in hospitalized COVID-19 patients. Prospective cohorts and RCTs are urgently needed in exploring the definitive effect of LMWH to provide direct high-certainty evidence. PROSPERO registration number: CRD42021271977
- 3 August 2022
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 8 (8) , 909-918
Open AccessLow molecular weight heparin is associated with better outcomes than unfractionated heparin for thromboprophylaxis in hospitalized COVID-19 patients: a meta-analysis
This study aimed to compare the outcomes of administration of LMWH and UFH in hospitalized COVID-19 patients. We systematically searched several databases and included observational studies or clinical trials that compared the outcomes of administration of LMWH and UFH in hospitalized COVID-19 patients. A total of nine studies comprising 9637 patients were included. Metanalysis showed that LMWH administration was associated with a lower in-hospital mortality, and 28/30-day mortality compared with UFH administration ([RR 0.44; 95%CI 0.32–0.61; I2:87.9%] and [RR 0.45; 95%CI 0.24–0.86; I2:78.4%], respectively). Patient with LMWH had shorter duration of hospital and ICU length of stay compared with UFH ([WMD −2.20; 95%CI −3.01 to −1.40; I2:0%] and [WMD −1.41; 95%CI −2.20 to −0.63; I2:0%], respectively). The risk of ICU admission or mechanical ventilation was lower in patients who received LMWH than those who received UFH (RR 0.67; 95%CI 0.55–0.81; I2:67.3%). However, there was no difference in the incidence of bleeding with LMWH compared with UFH (RR 0.27; 95%CI 0.07–1.01; I2:64.6%). Our meta-analysis showed that administration of LMWH was associated with better outcomes compared with UFH in hospitalized COVID-19 patients. Prospective cohorts and RCTs are urgently needed in exploring the definitive effect of LMWH to provide direct high-certainty evidence. PROSPERO registration number: CRD42021271977